Health Canada approves MedMira’s Reveal® Rapid TP Test – Urgent New Tool In The Battle Against Syphilis

Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada. A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in […]
MedMira Announces Launch of Clinical Trial for Its Multiplo® TP/HIV Self-Test in Canada

Halifax, Nova Scotia, July 16, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira’s Multiplo® TP/HIV rapid test for use as a self-test in Canada. MedMira has been able to move forward with this label claim and avoid […]
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence

Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira’s Service-Disabled Veteran-Owned […]
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows MedMira to expedite its growth in the Canadian market with the recently Health Canada approved Multiplo® TP/HIV rapid antibody test and its Reveal® G4 HIV-1/2 rapid […]
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test – A Potential Game Changer to Address Syphilis Health Crisis in Canada

Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed in Canada. The new Multiplo® TP/nTP will provide a complete system which combines screening and confirmation in […]
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio […]
Corporate Update on Clinical Evaluation of MedMira’s Products

Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended […]
MedMira receives 3 new trademarks

MedMira has been notified that the Company has successfully defended its claim on its submitted trademarks. VYRAU.S. Serial Number: 90407022 BYRAU.S. Serial Number: 90407042 PYRAU.S. Serial Number: 90407030 Registration certification will be issued in the coming weeks.
MedMira provides Progress Update

Halifax, Nova Scotia, 30 September, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market. U.S. Regulatory Update on COVID-19 Products The recent announced recommendation by the U.S. FDA to […]
Test yourself in a smart way

A fact sheet for the importance of testing for both TP/nTP. Multiplo® Compete Syphilis (TP/nTP) Antibody Test – testing was never so easy and fast. Take YOUR health in YOUR hands. Download TP/nTP general public fact sheet